Showing 1191 results
- Media Release /SMS for Life 2.0 launches for the first time in Kaduna State, Nigeria's third most populous region, in collaboration with the Kaduna State Ministry of Health Program uses smartphones and…
- Media Release /
Novartis lance SMS for Life 2.0 au Nigeria pour aider à améliorer l'accès aux médicaments essentiels
SMS for Life 2.0 est lancé pour la première fois dans l'Etat de Kaduna, troisième région la plus peuplée du Nigeria, en collaboration avec le ministère de la Santé de l'Etat de Kaduna. Ce… - Media Release /"SMS for Life 2.0" wird zum ersten Mal im Bundesstaat Kaduna, der bevölkerungsreichsten Region Nigerias, in Zusammenarbeit mit dem Gesundheitsministerium von Kaduna eingeführt. Das Programm nutzt…
- Media Release /Two pivotal Phase III studies did not show additional improvement in best corrected visual acuity (BCVA) for pegpleranib and Lucentis (ranibizumab) combination treatment over standard of care…
- Media Release /MONALEESA-2 analyses demonstrate superior PFS with LEE011 plus letrozole in pre-defined patient subgroups - from de novo to bone, liver and lung metastases - compared to letrozole alone …
- Media Release /Subgroup of patients had a 25% reduction in major adverse cardiovascular events when treated with canakinumab in a new analysis of Phase III CANTOS trial presented at the American Heart Association…
- Media Release /RTH258 demonstrates superiority versus aflibercept in key secondary endpoint measures of disease activity and meets primary endpoint of non-inferiority in patients with nAMD AMG 334 has a…
- Media Release /Entresto reversed trend of worsening New York Heart Association (NYHA) class - a key measure of the severity of a patient's heart failure symptoms - improving common…
- Media Release /Poor patients in Punjab will have access to high-quality medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will…
- Key Release /Brolucizumab, the first and only anti-VEGF to maintain a majority of patients on a 12-week treatment schedule immediately following loading phase in Phase III trials, met primary endpoint of non-…
Pagination
- ‹ Previous page
- 1
- …
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- …
- 120
- › Next page